ArticleThe oncologist2026
Metabolic profile and skeletal muscle as predictors of survival in testicular germ cell tumors.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTesticular germ cell tumors (TGCT) are highly curable malignancies, yet the prognostic impact of host metabolic status remains underexplored, especially in non-Caucasian populations.
methodsWe analyzed 2755 Mexican patients with TGCT treated at the Instituto Nacional de Cancerología (2007-2021). A Metabolic sub-cohort (n = 586) and an Imaging sub-cohort (n = 231) with baseline CT-derived lean mass index (LMI) were evaluated. Statistical analyses included multivariate Cox regression adjusted for IGCCCG risk, principal component analysis (PCA)-based clustering, and internal validation using bootstrapping.
resultsMultivariate Cox regression adjusted for IGCCCG risk identified LMI (HR 0.95, 95% CI 0.90-0.99, P = .047), serum albumin (HR 0.27, 95% CI 0.18-0.42, P < .001), and HDL cholesterol (HR 0.94, 95% CI 0.91-0.96, P < .001) as independently associated factors. PCA-based metabolic-nutritional risk profiles effectively stratified 5-year survival in patients with non-seminoma (from 16.1% in depleted profiles to 97.4% in preserved profiles) and seminoma (64.0% vs 100%). A reduced prognostic model (BMI, LMI, albumin) achieved a robust optimism-corrected AUC of 0.866.
conclusionsMetabolic and body composition profiling provides prognostic discrimination complementary to the IGCCCG classification, suggesting the potential utility of incorporating objective nutritional assessments. Early identification of patients with metabolic vulnerability-specifically hypoalbuminemia, skeletal muscle depletion, and altered lipid profiles-could help guide personalized supportive strategies prioritizing nutritional and medical optimization to improve outcomes in TGCT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.